The Global Health Body Sounds Alert Over Severe Lack of Obesity Medications
Under 10% of people eligible to benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it releases its initial recommendations on the drugs.
With more than one billion individuals worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per projections, more than two billion could be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key obstacles to broad access to the injections that can aid individuals in losing significant body mass, explains the body.
Skinny Jab Scarcity
Even in the present best projected case, the manufacturing of such drugs might only reach around 100 million people – under 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to expand availability, by approaches including voluntary licensing.
The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Operate
These medications mimick a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so people reduce food intake.
Patients usually begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence suggests patients may put most of the weight back on a year later of stopping the treatment, as their typical appetite return.
Being carrying excess weight increases your risk for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
